Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients

Autor: R. Bonanthaya, B.K.M. Reddy, K.G. Babu, Kamalaksha Shenoy, M. S. Vidyasagar, V. Lokesh, Loknatha, Nanjundappa, Ashok M. Shenoy, Jayarama K. Shetty, Krishna Prasad, C.R. Tanvir Pasha, T. Naveen, Bindhu Joseph, P.P. Bapsy

Publikováno v: Oral oncology. 50(5)

Summary Objective Overexpression of epidermal growth factor receptor (EGFR) in many cancers makes it an attractive therapeutic target. This study evaluated the clinical utility of nimotuzumab, a monoclonal anti-EGFR antibody, used concurrently with r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61e35cd9ad16d5f2fda7756b289756a7
https://pubmed.ncbi.nlm.nih.gov/24613543

An open-label, randomized, study of h-R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): Four-year survival results from a phase IIb study

Autor: P.P. Bapsy, C. T. Pasha, Ashok M. Shenoy, Bindhu Joseph, A S Aravind, K.G. Babu, T. Naveen, B.K.M. Reddy, Lokesh Viswanath, Kamalaksha Shenoy, N Gupta, A Eswaraiah, M. S. Vidyasagar, R. Bonanthaya

Publikováno v: Journal of Clinical Oncology. 28:5530-5530

5530 Background: h-R3mAb (nimotuzumab) is a humanized monoclonal antibody targeting epidermal growth factor receptor (EGFR). EGFR is over-expressed in >90% squamous cell carcinoma of head and neck (SCCHN). Patients with advanced inoperable SCCHN have

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d825d7c6c606e0bf5bf7219da539e0e9
https://doi.org/10.1200/jco.2010.28.15_suppl.5530

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A child with acute lymphocytic leukaemia.

Autor: Bonanthaya R; Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore, India., Appaji L; Department of Paediatric Oncology, Kidwai Memorial Institute of Oncology, Bangalore, India., Lakshmaiah KC; Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore, India.

Publikováno v: Malawi medical journal : the journal of Medical Association of Malawi [Malawi Med J] 2014 Jun; Vol. 26 (2), pp. 51-2.